Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas G von Lueder

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Cardiovascular Drugs and Therapy|December 11, 2012
RAAS inhibitors and cardiovascular protection in large scale trialsThomas G von Lueder, Henry Krum
Cardiology|March 24, 2016
The Prognostic Role of Serum Uric Acid (SUA) in Coronary Artery Disease: PerSUAsive Data Plea for a Large Morbidity-Mortality TrialThomas G von Lueder, Nicolas Girerd
Heart (British Cardiac Society)|May 11, 2012
Current modalities for invasive and non-invasive monitoring of volume status in heart failureThomas G von Lueder, Henry Krum
Circulation Journal : Official Journal of the Japanese Circulation Society|March 10, 2015
Qualifying the use of common cardiovascular drugs in cardiologyDipak Kotecha, Thomas G von Lueder
Nature Reviews. Cardiology|September 30, 2015
New medical therapies for heart failureThomas G von Lueder, Henry Krum
Heart Failure Clinics|March 25, 2014
Comorbidities and polypharmacyThomas G von Lueder, Dan Atar
Journal of Thoracic Disease|July 20, 2018
The burden of heart failure in the general population: a clearer and more concerning pictureThomas G von Lueder, Stefan Agewall
Pharmacology & Therapeutics|May 20, 2014
Current role of neprilysin inhibitors in hypertension and heart failureThomas G von Lueder, Dan Atar, Henry Krum
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2019
Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapySverre E Kjeldsen, Dan Atar, Thomas G von Lueder
Cardiology|March 8, 2016
In memoriam Henry Krum, 1958-2015Thomas G von Lueder, Ingrid Hopper, Dipak Kotecha, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Cardiovascular Drugs and Therapy|December 11, 2012
RAAS inhibitors and cardiovascular protection in large scale trialsThomas G von Lueder, Henry Krum
Cardiology|March 24, 2016
The Prognostic Role of Serum Uric Acid (SUA) in Coronary Artery Disease: PerSUAsive Data Plea for a Large Morbidity-Mortality TrialThomas G von Lueder, Nicolas Girerd
Heart (British Cardiac Society)|May 11, 2012
Current modalities for invasive and non-invasive monitoring of volume status in heart failureThomas G von Lueder, Henry Krum
Circulation Journal : Official Journal of the Japanese Circulation Society|March 10, 2015
Qualifying the use of common cardiovascular drugs in cardiologyDipak Kotecha, Thomas G von Lueder
Nature Reviews. Cardiology|September 30, 2015
New medical therapies for heart failureThomas G von Lueder, Henry Krum
Heart Failure Clinics|March 25, 2014
Comorbidities and polypharmacyThomas G von Lueder, Dan Atar
Journal of Thoracic Disease|July 20, 2018
The burden of heart failure in the general population: a clearer and more concerning pictureThomas G von Lueder, Stefan Agewall
Pharmacology & Therapeutics|May 20, 2014
Current role of neprilysin inhibitors in hypertension and heart failureThomas G von Lueder, Dan Atar, Henry Krum
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2019
Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapySverre E Kjeldsen, Dan Atar, Thomas G von Lueder
Cardiology|March 8, 2016
In memoriam Henry Krum, 1958-2015Thomas G von Lueder, Ingrid Hopper, Dipak Kotecha, et al.
Pageof 5